D91597Z
Brachytherapy Tongue to None with Cesium 137 (Cs-137), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | 5 Tongue |
| Approach | 9 High Dose Rate (HDR) |
| Device | 7 Cesium 137 (Cs-137) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Tongue
The tongue's soft, mobile tissue and rich vascularity make it well suited to interstitial brachytherapy, in which radioactive sources are threaded through the tongue via catheters to deliver a highly localized dose directly into or around a tumor. This technique is particularly valuable for smaller, well-defined lesions of the mobile tongue where a boost dose or standalone implant can achieve tumor control while sparing more tissue than external radiation alone, preserving speech and swallowing function. Because the tongue moves constantly and its tissue is compressible, catheter placement requires careful technique to ensure sources remain correctly positioned relative to the tumor throughout treatment. The procedure is typically performed under anesthesia given the discomfort of implantation, and documentation should reflect the tongue as the specific implanted site.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Cesium 137 (Cs-137)
Cesium 137 (Cs-137) identifies the specific radioactive isotope used as the source in a radiation therapy procedure, most often in brachytherapy applications. Naming the isotope distinguishes the treatment's radiation source from other isotopes or from external beam techniques that carry a None qualifier. It matters clinically because different isotopes have distinct energy profiles and dosing implications.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.